2014
DOI: 10.2337/db14-rt05b
|View full text |Cite
|
Sign up to set email alerts
|

Update of Retraction—Blockade of Receptor for Advanced Glycation End Products in a Model of Type 1 Diabetic Leukoencephalopathy. Diabetes. 19 November 2012 [Epub ahead of print]. DOI: 10.2337/db12-0317

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2014
2014

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Although numerous factors contributing to the development of diabetic complications have been proposed, advanced glycation end products (AGEs) which have a wide range of chemical, cellular, and tissue effects through changes in electrostatic property, solubility, and conformation have been receiving much attention in recent studies [1,2,3,4]. AGEs are irreversible endproducts of protein glycation reaction, known collectively as Maillard or nonenzymatic reactions with the production of free redicals [5,6].…”
Section: Introductionmentioning
confidence: 99%
“…Although numerous factors contributing to the development of diabetic complications have been proposed, advanced glycation end products (AGEs) which have a wide range of chemical, cellular, and tissue effects through changes in electrostatic property, solubility, and conformation have been receiving much attention in recent studies [1,2,3,4]. AGEs are irreversible endproducts of protein glycation reaction, known collectively as Maillard or nonenzymatic reactions with the production of free redicals [5,6].…”
Section: Introductionmentioning
confidence: 99%